VIRI Sep 2024 7.500 call
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 7.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Insider MonkeyVirios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript May 11, 2024 Virios Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Virios Therapeutics Incorporated First Quarter 2024 Earnings Call. At this time, […]
GlobeNewswireVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“
- GlobeNewswire
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30
